By Tony Fong

NEW YORK (GenomeWeb News) – As Epigenomics prepares to enter the US market, it plans to meet with the US Food and Drug Administration in the coming weeks and to hire someone to direct its commercial operations in the US.

On the sidelines of the JP Morgan Healthcare Conference last week in San Francisco, an official from the German molecular diagnostics firm outlined the company's plan to break into the US market with its lead product, the Epi proColon test for the early detection of colon cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.